Intranasal Peptide Delivery to the Brain
Peptide Delivery and Inhalation
2 Routes
Two direct nerve pathways, olfactory and trigeminal, transport peptides from the nasal cavity to the brain without crossing the blood-brain barrier.
Meredith et al., The AAPS Journal, 2015
Meredith et al., The AAPS Journal, 2015
View as imageThe blood-brain barrier blocks more than 98% of small molecules and virtually all large molecules from entering the brain. For peptide therapeutics targeting neurological conditions, this barrier is the central engineering problem: a peptide injected into the bloodstream may never reach brain tissue in meaningful concentrations. Intranasal delivery offers a potential workaround. The nasal cavity contains nerve endings that project directly into the brain, and research over the past two decades has shown that peptides sprayed into the nose can travel along these neural pathways to reach central nervous system targets. The pillar article on inhaled peptide drugs covers pulmonary delivery for systemic absorption. This article focuses specifically on nose-to-brain transport, the mechanisms behind it, and where clinical evidence stands. For the closely related topic of how the transport pathways themselves function, see the sibling article on nose-to-brain transport mechanisms.
Key Takeaways
- The olfactory nerve pathway connects the upper nasal cavity directly to the olfactory bulb and from there to deeper brain regions, bypassing the blood-brain barrier entirely
- The trigeminal nerve pathway provides a second direct route from the nasal cavity to the brainstem and other CNS structures
- Intranasal oxytocin has been tested in over 100 clinical trials for autism, social behavior, and psychiatric conditions, making it the most extensively studied nose-to-brain peptide (Veening and Olivier, 2013)
- A large NEJM trial by Sikich et al. (2021) found that intranasal oxytocin did not improve social behavior in 290 children with autism, tempering earlier optimistic findings from smaller studies
- Intranasal neuropeptide Y (NPY) showed promise for PTSD prevention in animal models by reaching amygdala targets within hours of nasal administration (Sabban et al., 2018)
- No nose-to-brain peptide formulation has received FDA approval as of 2026, though several peptides (oxytocin, insulin, NPY) are in advanced clinical testing
The Anatomy That Makes Nose-to-Brain Transport Possible
The nasal cavity is not a simple tube. Its upper region, the olfactory epithelium, contains approximately 6 million olfactory receptor neurons in humans. These neurons are unusual: their cell bodies sit in the nasal mucosa, but their axons project through tiny holes in the cribriform plate (a bone at the top of the nasal cavity) directly into the olfactory bulb of the brain. This direct neural connection is the anatomical basis of smell, and it creates a potential highway for drug delivery.
Meredith et al. (2015) reviewed the mechanisms of intranasal protein and peptide delivery in The AAPS Journal. They identified two primary transport routes:[1]
The olfactory pathway. Peptides deposited on the olfactory epithelium can be taken up by olfactory neurons through receptor-mediated endocytosis or fluid-phase pinocytosis. Once inside the neuron, the peptide travels along the axon (intracellular transport) through the cribriform plate into the olfactory bulb. From there, it can distribute to the hippocampus, cortex, and other brain regions. Alternatively, peptides can travel along the outside of olfactory nerve fibers (extracellular transport) through the perineural space. This extracellular route is faster, potentially delivering molecules to the brain within minutes rather than hours.
The trigeminal pathway. The trigeminal nerve (cranial nerve V) innervates the respiratory epithelium of the nasal cavity. Its branches carry sensory information from the face, and its axons project to the brainstem. Peptides absorbed by trigeminal nerve endings in the nose can travel along these axons to reach the pons, medulla, and from there potentially distribute to other brain areas.
A third route exists but is less direct: peptides absorbed through the nasal vasculature enter the systemic circulation and may cross the blood-brain barrier at low efficiency, the same way any intravenously administered peptide would. This route does not provide the selective brain targeting advantage that distinguishes intranasal from other delivery methods.
Intranasal Oxytocin: The Most Studied Case
Oxytocin is a 9-amino-acid peptide hormone involved in social bonding, trust, and emotional processing. Because its therapeutic targets (amygdala, prefrontal cortex, nucleus accumbens) are in the brain, and because oxytocin does not efficiently cross the blood-brain barrier from the bloodstream, intranasal delivery became the primary clinical approach.
Early Promise
Veening and Olivier (2013) reviewed the behavioral and clinical effects of intranasal oxytocin in Neuroscience and Biobehavioral Reviews. They cataloged evidence that single-dose intranasal oxytocin increased trust, improved facial emotion recognition, enhanced in-group favoritism, and reduced anxiety in healthy volunteers. Brain imaging studies showed that intranasal oxytocin altered activity in the amygdala and other socially relevant brain regions within 45 minutes of administration.[2]
Parker et al. (2017) published a study in PNAS showing that intranasal oxytocin improved social responsiveness scores in children with autism spectrum disorder (ASD) over a 4-week treatment period. The study also identified potential biomarkers of response, including baseline salivary oxytocin levels and DNA methylation patterns of the oxytocin receptor gene.[3]
Bethlehem et al. (2017) used functional MRI to demonstrate that a single dose of intranasal oxytocin enhanced corticostriatal functional connectivity in women, providing direct neuroimaging evidence that nasally administered oxytocin modifies brain network activity.[4]
The Reality Check
The largest and most rigorous trial told a different story. Sikich et al. (2021) published in the New England Journal of Medicine a multicenter, randomized, placebo-controlled trial of intranasal oxytocin in 290 children and adolescents with ASD. Over 24 weeks of treatment, intranasal oxytocin did not improve social functioning compared to placebo on the primary outcome measure (Aberrant Behavior Checklist modified Social Withdrawal subscale) or any secondary measures.[5]
Yamasue et al. (2020) reported similar results in a Japanese trial: intranasal oxytocin did not improve core social symptoms in adults with ASD in a 6-week randomized controlled trial published in Molecular Psychiatry.[6]
These negative results raise questions that extend beyond oxytocin itself. The failure could reflect problems with the delivery method (not enough oxytocin reaching the right brain regions), the therapeutic hypothesis (oxytocin may not be the right target for ASD social deficits), or both. The fact that small studies showed effects while large studies did not is a pattern seen across many fields and often indicates that initial positive results were inflated by publication bias, underpowered statistics, or uncontrolled variables.
Intranasal Neuropeptide Y: PTSD and Depression
Neuropeptide Y (NPY) is a 36-amino-acid peptide involved in stress resilience, anxiety regulation, and fear extinction. Low NPY levels correlate with PTSD vulnerability, making it a candidate for preventive or therapeutic intervention. Because NPY's relevant targets (amygdala, prefrontal cortex, hippocampus) are deep brain structures, intranasal delivery is being explored as the route most likely to achieve therapeutic concentrations.
Sabban et al. (2018) reviewed the potential of intranasal NPY for preventing or treating PTSD in Military Medicine. Animal studies showed that intranasal NPY administration reached the amygdala within hours, reduced anxiety-like behavior, and prevented the development of PTSD-like symptoms in stress-exposed rats. The authors proposed that intranasal NPY could be administered shortly after trauma exposure as a preventive intervention.[7]
Nahvi et al. (2021) extended this work to depression models in female rodents, demonstrating that intranasal NPY reduced depressive-like behavior in the single prolonged stress model. The effect was specifically localized to brain regions accessible via the nose-to-brain route, supporting the hypothesis that intranasal delivery was achieving central rather than peripheral effects.[8]
The NPY intranasal data is entirely preclinical. No published human trials have tested intranasal NPY for PTSD or depression endpoints. The path from rodent behavioral models to human psychiatric outcomes is long and filled with failures; the oxytocin story is instructive.
Intranasal Insulin: Alzheimer's Disease Research
Insulin receptors are densely expressed in the hippocampus and cortex, brain regions critical for memory. Insulin signaling in the brain regulates glucose metabolism, synaptic plasticity, and neuronal survival. In Alzheimer's disease, brain insulin signaling is impaired, leading some researchers to describe the condition as "type 3 diabetes."
Intranasal insulin has been tested in clinical trials for Alzheimer's disease and mild cognitive impairment. Early-phase trials reported improvements in delayed memory recall and cerebral blood flow in insulin-treated patients compared to placebo. A 2025 brain imaging study confirmed that intranasally delivered insulin reaches key memory regions of the brain in older adults.
The intranasal insulin results are more encouraging than the oxytocin-for-ASD data, but they come with important caveats. Sample sizes remain small, the effect sizes are modest, and the optimal insulin formulation and delivery device have not been standardized. Different studies used different devices (some use a specialized ViaNase nebulizer, others use simple nasal sprays), making cross-study comparisons difficult.
Pihoker et al. (1997) provided early proof-of-concept that peptide hormones could be delivered intranasally with clinical effect, demonstrating that intranasal growth hormone-releasing peptide-2 (GHRP-2) stimulated growth hormone release in children with short stature. This study, published in The Journal of Endocrinology, showed that nasal peptide delivery could produce systemic pharmacological effects, though it did not specifically investigate brain delivery.[9]
Cell-Penetrating Peptides: Enhancing Nose-to-Brain Transport
A major limitation of intranasal peptide delivery is the biological barrier of the nasal epithelium itself. Even in the olfactory region, tight junctions between epithelial cells restrict paracellular transport, and enzymatic degradation in the nasal mucus layer destroys a portion of the administered peptide before it can be absorbed.
Cell-penetrating peptides (CPPs) are being investigated as tools to enhance intranasal delivery. These short, typically cationic peptide sequences (most famously TAT, derived from HIV-1) can carry cargo across cell membranes. When conjugated to therapeutic peptides or formulated as part of nasal delivery systems, CPPs may increase the fraction of administered dose that reaches brain tissue.
Derakhshankhah and Jafari (2018) reviewed cell-penetrating peptide applications in biomedicine, noting that CPP-mediated delivery systems have been tested for nose-to-brain transport of insulin, nerve growth factor, and various neuropeptides in animal models.[10] However, CPP-enhanced intranasal delivery has not been tested in human clinical trials for brain-targeting applications.
This approach also connects to the broader field of how cell-penetrating peptides escape endosomes once inside cells, a challenge that applies whether the entry point is the nose, the gut, or a direct injection site.
Practical Challenges and Limitations
Several fundamental challenges limit the clinical translation of nose-to-brain peptide delivery:
Dose uncertainty. The fraction of a nasal dose that actually reaches the brain (versus being absorbed systemically, swallowed, or degraded locally) is difficult to measure in humans. Animal studies using radiolabeled peptides suggest that brain delivery represents a small percentage of the administered dose, possibly 1-5%. Whether this is enough for therapeutic effect depends on the peptide and the target.
Mucociliary clearance. The nasal mucosa has a rapid clearance mechanism that moves deposited substances toward the throat within 15 to 20 minutes. This limits the time available for peptide absorption through olfactory or trigeminal pathways. Various formulation strategies (mucoadhesive polymers, gelling agents, nanoparticles) attempt to extend residence time.
Device dependence. Where a nasal spray deposits its contents in the nasal cavity matters enormously. The olfactory epithelium occupies a small area at the top of the nasal cavity. Standard nasal spray devices deposit most of their contents on the lower respiratory epithelium, which primarily leads to systemic absorption rather than brain delivery. Specialized devices designed to target the upper nasal cavity are under development but add cost and complexity.
Enzymatic degradation. The nasal mucosa contains peptidases that break down peptide molecules. Larger peptides and proteins are particularly vulnerable. Formulation strategies including enzyme inhibitors, PEGylation, and encapsulation in nanoparticles aim to protect peptides from degradation, but each adds manufacturing complexity.
Regulatory pathway. No nose-to-brain peptide product has received FDA approval. The regulatory framework for demonstrating brain delivery in humans remains unclear. Conventional pharmacokinetic studies measure drug levels in blood; demonstrating brain penetration requires expensive imaging studies or cerebrospinal fluid sampling.
For comparison with other delivery challenges facing peptide drugs, the article on oral peptide delivery covers the parallel efforts to overcome gastrointestinal barriers, and the Semax/Selank peptides discussed in intranasal nootropic research represent peptides already marketed as nasal sprays in Russia.
The Bottom Line
Intranasal delivery offers a potential route for peptides to bypass the blood-brain barrier via olfactory and trigeminal nerve pathways. Oxytocin is the most extensively tested intranasal peptide, but large RCTs have failed to confirm the social behavior improvements seen in smaller studies. Intranasal NPY shows preclinical promise for PTSD. Intranasal insulin is being investigated for Alzheimer's disease. No nose-to-brain peptide product has received FDA approval, and fundamental challenges in dose quantification, device design, and regulatory pathways remain unresolved.